ImmunGene's Series A Round

ImmunGene raised a round of funding on November 07, 2013. Investors include Ally Bridge Group.

ImmunGene is a privately held biotechnology company focused on the development of antibody-cytokine fusion technology and monoclonal antibody-based therapies to treat cancer, autoimmune disorders, and…

Articles about ImmunGene's Series A Round: